Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Lutathera (lutetium Lu 177 dotatate) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumours

Drug (Brand / Generic)

Lutathera®/lutetium Lu 177 dotatate

Developed by

Advanced Accelerator Applications

Therapy Class

Peptide receptor radionuclide therapy (PRRT)

Current Indication

Gastroenteropancreatic neuroendocrine tumours

Market Sector

Oncology

Development Status

Approved in the US and Europe
Expand

Go Top